Zai Lab Strengthens Oncology Pipeline with US$ 338 M Mirati Alliance in Greater China

By Swati Sharan & Michelle Liu

Pharma Deals Review: Vol 2021 Issue 6 (Table of Contents)

Published: 29 Jun-2021

DOI: 10.3833/pdr.v2021.i6.2617     ISSN: 1756-7874

Section: Research & Development



In a bid to broaden its lung cancer franchise, Zai Lab has entered into a collaboration and license agreement with Mirati Therapeutics to develop and commercialise adagrasib for the treatment of cancer associated with KRAS G12C mutationin Greater China...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details